Subscribe Newsletter
Facebook-f Twitter Linkedin

Placozoans: Nature’s Marvels and Their Potential in Cancer Research

Read More

Why Neoantigens Pose Challenges for Cancer Immunotherapy

Read More

Development of Dual-Targeting CAR-T Cells for Enhanced Specificity and Efficacy in Solid Tumors

Read More

Understanding the Rarity of Cancer in Newborns:

Read More

Read More

Most viewed

View more

Most viewed

Popular Categories

Cancer Biology
Immunology
Cancer Biology
Our goal is to provide reliable information to Life Science Scientists which include but not limited to latest news in technology and availability of grants outside the NIH and NSF grants and other useful information that Scientists can use to advance their research. We update this information on a daily basis. This information has saved scientists the hundreds of hours necessary to search out that information independently. As a result it has allowed our readers to focus more closely on what you do best Scientific research.
Home
About Us
Blog
Contact Us
Terms & condition
Privacy policy
Social Media
Facebook-f Twitter Linkedin-in
Copyright 2023
escienceinfo-logo
Sign up to Stay in Touch!
About eScience Info’s Newsletter This is a free weekly eNewsletter for Life Science Scientists. eScienceInfo has established itself as the leading provider of up-to-the-minute information for Scientists. Now, we’re enhancing our services to better meet the needs of our readers. For years we’ve searched out the latest grants available and consolidated the information into one easy-to-read e-newsletter. Then we delivered it right to your inbox to save you the hundreds of hours that it would take to search out that information yourself.
By submitting this form, you are consenting to receive marketing emails from: eScience Info LLC, 4990 Sadler Place , Unit #4982, GLEN ALLEN, VA 23058-1323, US, http://www.escienceinfo.com You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.